We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters to the Editor |

Atypical Antipsychotics and Cognition in Schizophrenia

Tonmoy Sharma, MD
Arch Gen Psychiatry. 2002;59(6):571-572. doi:.
Text Size: A A A
Published online


Purdon et al1 have presented, with many qualifications, results from a double-blind randomized trial comparing the cognitive benefits of olanzapine, risperidone, and haloperidol. Studies of this type are important; however, the interpretation of the referenced study requires caution, and the clinical relevance of the data is limited.

In disclosing the increasing interest in slower titration and lower doses of risperidone than were used in the trial, the authors assert that the dosing schema they used was valid because it was consistent with the relevant product monograph and with the doses used in an earlier study.2 Emerging data and clinical practice often lead advances in the standard of care, and changes to product literature lag behind. Also, the study that was cited for setting a dosing precedent was conducted in a refractory population that can be expected to require higher medication doses. A more credible discussion of the aberrantly high doses of risperidone used in the trial would be made by using audited pharmacy data to get a realistic assessment of the average daily doses used in practice at the participating centers.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

4 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.